RUNX1 and acute myeloid leukemia: We do not know, for example, if oncogene mutations such as ASXL2, KMT2A, and TET2 in CN-AMLs have any biological influence in AML1-ETO-postive AML or if the co-occurrences of driver genes with AML1-ETO would contribute to poor clinical outcomes.